MR
Therapeutic Areas
Kala Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KPI-012 | Persistent Corneal Epithelial Defects (PCED) | Phase 2b |
Leadership Team at Kala Pharmaceuticals
MI
Mark Iwicki
Chairman, President and Chief Executive Officer
EL
Eric L. Trachtenberg
Chief Financial Officer
KM
Kimberly M. Lee
Chief Corporate Strategy Officer and Head of Investor Relations
AR
Andrew R. Gow, Ph.D.
Chief Scientific Officer
MS
Marcio Souza
Board Director
RM
Rajeev M. Shah
Board Director
CY
Christopher Y. Chai
Board Director